Published in Gut on March 01, 1996
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ (2001) 2.15
Clinical review: Major consequences of illicit drug consumption. Crit Care (2008) 1.79
Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver. Proteomics (2008) 1.03
Ten years of 'ecstasy'. J R Soc Med (1999) 1.02
Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci (2013) 0.95
Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage. Curr Pharm Biotechnol (2010) 0.88
Successful treatment of refractory cerebral oedema in ecstasy/cocaine-induced fulminant hepatic failure using a new high-efficacy liver detoxification device (FPSA-Prometheus). Wien Klin Wochenschr (2003) 0.88
Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut (1999) 0.85
Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine ("ecstasy"). Toxicol Lett (2009) 0.85
Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy). Iran J Basic Med Sci (2013) 0.82
The effects of ecstasy on liver function tests, blood glucose, and lipids profile of male rats. Int J High Risk Behav Addict (2014) 0.77
Ecstasy-induced recurrent toxic hepatitis in a young adult. Curr Ther Res Clin Exp (2008) 0.75
A bibliometric analysis of exertional heat stroke research in Web of Science. Mil Med Res (2016) 0.75
Management of drug abuse emergencies. J Accid Emerg Med (1996) 0.75
Ecstasy-induced myocardial infarction in a teenager: rare complication of a widely used illicit drug. Clin Res Cardiol (2010) 0.75
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") Lancet (1992) 7.01
'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. JAMA (1987) 4.49
Heatstroke: its clinical picture and mechanism in 36 cases. Q J Med (1967) 3.08
Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') JAMA (1987) 2.70
Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med (1991) 2.42
Hyponatraemia after ingestion of ecstasy. BMJ (1994) 2.05
Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav (1991) 1.76
Acute heat stroke. Epidemiologic, biochemical, renal, and coagulation studies. JAMA (1975) 1.29
Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res (1990) 1.16
Environmental and drug-induced hyperthermia. Pathophysiology, recognition, and management. Emerg Med Clin North Am (1984) 1.16
Cerebral infarction in association with Ecstasy abuse. Postgrad Med J (1993) 1.08
Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve'). Anaesthesia (1993) 1.07
Misuse of ecstasy. BMJ (1992) 1.00
Ecstasy induced hepatitis mimicking viral hepatitis. Gut (1995) 0.98
The liver in fatal exertional heatstroke. Liver (1983) 0.92
Heat stroke. Report of three fatal cases with emphasis on findings in skeletal muscle. Arch Pathol Lab Med (1980) 0.90
Liver failure occurring as a component of exertional heatstroke. Gastroenterology (1991) 0.87
Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C. Anaesthesia (1993) 0.86
[Acute liver failure caused by methylenedioxymethamphetamine ('ecstasy')]. Ned Tijdschr Geneeskd (1993) 0.85
Heatstroke and rhabdomyolysis presenting as fulminant hepatic failure. Postgrad Med J (1988) 0.80
Attached, detached, or new recruits? BMJ (1992) 0.79
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Liver transplantation. Curr Probl Surg (1979) 2.57
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25
Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20
Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16
Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14
Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem (1989) 2.14
Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12
A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology (1995) 2.11
H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet (1977) 2.10
The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther (2014) 2.10
Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J (1973) 2.09
Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet (1993) 2.09
Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis (1970) 2.09
Detection, treatment, and follow up of women with Chlamydia trachomatis infection seeking abortion in inner city general practices. BMJ (1989) 2.08
Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08
Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet (1971) 2.08
Cell-mediated immune responses in chronic liver diseases. Br Med J (1972) 2.05
Inheritance and expression of chimeric genes in the progeny of transgenic maize plants. Biotechnology (N Y) (1990) 2.05
Chondrocalcinosis and arthropathy: studies in haemochromatosis and in idiopathic chondrocalcinosis. Q J Med (1970) 2.03
Development and importance of health needs assessment. BMJ (1998) 2.03
Hereditary spherocytosis with secondary haemochromatosis. Lancet (1968) 2.00
Liver transplantation in man: the frequency of rejection, biliary tract complications, and recurrence of malignancy based on an analysis of 26 cases. Gastroenterology (1973) 1.99
Evidence that hepatitis D virus needs hepatitis B virus to cause hepatocellular damage. Am J Clin Pathol (1992) 1.98